netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Search
 Formulary Chapter 11: Eye - Full Chapter
Notes:

Preservative-free (PF) formulations - Preservative intolerance should be diagnosed by an ophthalmologist. If PF formulation is warranted, proprietary preservative-free formulations (often available as unit dose preparations) should be prescribed if at all possible. Manufactured “specials” are unlicensed and almost invariably cost significantly more.  PF formulations are appropriate, for example when a patient wears soft contact lenses or daily disposable contact lenses and wearing glasses instead is not a viable option such as for long courses OR where patient shows signs of preservative toxicity sometimes seen with multiple daily administrations.

 Details...
11.08.02  Expand sub section  Ocular diagnostic and peri-operative preparations and photodynamic treatment
11.08.02  Expand sub section  Subfoveal choroidal neovascularisation
Aflibercept (Eylea)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
BlueTeq

Restriction: In line with NICE Guidance only

 
Link  NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Link  NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
Link  NICE TA409 : Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA486: Aflibercept for treating choroidal neovascularisation
   
BrolucizumabBlack Triangle (Beovu)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
BlueTeq

Restriction: In line with NICE Guidance only

 
Link  NICE TA672: Brolucizumab for treating wet age-related macular degeneration
   
Ranibizumab (Lucentis)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
BlueTeq

Restriction: In line with NICE Guidance only

 
Link  NICE TA155 - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Link  NICE TA274: Ranibizumab for treating diabetic macular oedema
Link  NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Link  NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
   
11.08.02  Expand sub section  Vitreomacular traction
Ocriplasmin (Jetrea)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
 
Link  NICE TA297: Ocriplasmin for treating vitreomacular traction
   
 ....
 Non Formulary Items
Bevacizumab intravitreal injection  (Avastin)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Pegaptanib Sodium  (Macugen)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA155: guidance on pegaptanib in AMD (August 2008)
 
Verteporfin  (Visudyne)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.  

Amber

Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.  

Amber E

Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)   

Green

Suitable first-line drugs for implementation in Primary Care  

On Formulary

South Staffs Formulary Choice  

netFormulary